TransCode Therapeutics Announced FDA Authorization to Proceed with First-In-Human Clinical Trial
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced today that it has received written authorization from the U.S.